These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 36992275)

  • 61. Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant.
    Stavaru C; Onu A; Lupulescu E; Tucureanu C; Rasid O; Vlase E; Coman C; Caras I; Ghiorghisor A; Berbecila L; Tofan V; Bowen RA; Marlenee N; Hartwig A; Bielefeldt-Ohmann H; Baldwin SL; Van Hoeven N; Vedvick TS; Huynh C; O'Hara MK; Noah DL; Fox CB
    Hum Vaccin Immunother; 2016 Apr; 12(4):1009-26. PubMed ID: 26618392
    [TBL] [Abstract][Full Text] [Related]  

  • 62. COVAX, vaccine donations and the politics of global vaccine inequity.
    de Bengy Puyvallée A; Storeng KT
    Global Health; 2022 Mar; 18(1):26. PubMed ID: 35248116
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Vaccine Innovation for Pandemic Preparedness: Patent Landscape, Global Sustainability, and Circular Bioeconomy in Post-COVID-19 era.
    Possas C; de Souza Antunes AM; de Oliveira AM; de Souza Mendes Santos CD; Ramos MP; de Oliveira Rodrigues Schumacher S; Homma A
    Circ Econ Sustain; 2021; 1(4):1439-1461. PubMed ID: 34888570
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Future access to HIV vaccines. Report from a WHO-UNAIDS Consultation, Geneva, 2-3 October 2000.
    AIDS; 2001 May; 15(7):W27-44. PubMed ID: 11399975
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Emerging Technologies for Low-Cost, Rapid Vaccine Manufacture.
    Kis Z; Shattock R; Shah N; Kontoravdi C
    Biotechnol J; 2019 Jan; 14(1):e1800376. PubMed ID: 30537361
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Influenza vaccine: globalization of public health stakes].
    Collin N; Briand S
    Med Trop (Mars); 2009 Aug; 69(4):322. PubMed ID: 19725377
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Charity or empowerment? The role of COVAX for low and middle-income countries.
    Holzer F; Roa TM; Germani F; Biller-Andorno N; Luna F
    Dev World Bioeth; 2023 Mar; 23(1):59-66. PubMed ID: 35307947
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Decolonising human rights: how intellectual property laws result in unequal access to the COVID-19 vaccine.
    Sekalala S; Forman L; Hodgson T; Mulumba M; Namyalo-Ganafa H; Meier BM
    BMJ Glob Health; 2021 Jul; 6(7):. PubMed ID: 34253631
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Shaping meeting to explore the value of a coordinated work plan for epidemic and pandemic influenza vaccine preparedness.
    Ruscio B; Bolster A; Bresee J;
    Vaccine; 2020 Apr; 38(16):3179-3183. PubMed ID: 32171576
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Better Pandemic Influenza Preparedness through Adjuvant Technology Transfer: Challenges and Lessons Learned.
    Lemoine CH; Nidom RV; Ventura R; Indrasari S; Normalina I; Santoso KP; Derouet F; Barnier-Quer C; Borchard G; Collin N; Nidom CA
    Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34063131
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Meeting vaccine formulation challenges in an emergency setting: Towards the development of accessible vaccines.
    Peletta A; Lemoine C; Courant T; Collin N; Borchard G
    Pharmacol Res; 2023 Mar; 189():106699. PubMed ID: 36796463
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Advancing mRNA technologies for therapies and vaccines: An African context.
    Kairuz D; Samudh N; Ely A; Arbuthnot P; Bloom K
    Front Immunol; 2022; 13():1018961. PubMed ID: 36353641
    [TBL] [Abstract][Full Text] [Related]  

  • 73. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Expert Views on COVAX and Equitable Global Access to COVID-19 Vaccines.
    Manriquez Roa T; Holzer F; Luna F; Biller-Andorno N
    Int J Public Health; 2021; 66():1604236. PubMed ID: 35035347
    [No Abstract]   [Full Text] [Related]  

  • 75. COVID-19 and Future Disease X in Circular Economy Transition: Redesigning Pandemic Preparedness to Prevent a Global Disaster.
    Possas C; Marques ETA; Risi JB; Homma A
    Circ Econ Sustain; 2021; 1(4):1463-1478. PubMed ID: 34888566
    [TBL] [Abstract][Full Text] [Related]  

  • 76. COVAX and equitable access to COVID-19 vaccines.
    Yoo KJ; Mehta A; Mak J; Bishai D; Chansa C; Patenaude B
    Bull World Health Organ; 2022 May; 100(5):315-328. PubMed ID: 35521037
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The art of partnerships for vaccines.
    Pagliusi S; Che Y; Dong S
    Vaccine; 2019 Sep; 37(40):5909-5919. PubMed ID: 31447125
    [TBL] [Abstract][Full Text] [Related]  

  • 78. TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines.
    Mermelstein S; Stevens H
    Pharmaceutics; 2021 Dec; 14(1):. PubMed ID: 35056944
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Challenges and successes for the grantees and the Technical Advisory Group of WHO's influenza vaccine technology transfer initiative.
    Grohmann G; Francis DP; Sokhey J; Robertson J
    Vaccine; 2016 Oct; 34(45):5420-5424. PubMed ID: 27506497
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.